Articles related to Hematology/Oncology

ASCO released updated recommendations for recurrent ovarian cancer that reinforce platinum-based doublet therapy as the preferred approach for platinum-sensitive disease and provide guidance for platinum-resistant disease, maintenance strategies, and monitoring. Recommendations were derived from a systematic review of studies published through 2025.

A phase 3 trial in extensive-stage small cell lung cancer found that adding concurrent thoracic radiotherapy to chemoimmunotherapy did not improve survival outcomes and was associated with higher toxicity. Investigators reported more adverse events and treatment-related deaths, raising safety concerns about this combination strategy.

An engineered probiotic strain delivering a modified IL-2 therapy directly within pancreatic tumors slowed tumor growth and enhanced immune activity in preclinical models. Combination studies with chemotherapy, radiotherapy, and immunotherapy showed additional activity, though human data are not yet available.

A repeat PSMA PET/CT scan detected recurrent disease in more than half of prostate cancer patients whose initial scan was negative. Findings altered management in nearly half of patients, particularly those with oligometastatic recurrence.

The FDA expanded approval of the CRISPR-based gene therapy Casgevy to include patients as young as 2 years with sickle cell disease or transfusion-dependent beta thalassemia. The decision was supported by pediatric phase 3 data demonstrating sustained reductions in disease burden.

A case-based application of FRESCO trial data positions fruquintinib as a third-line option in KRAS-mutant metastatic colorectal cancer, while emphasizing treatment decisions shift toward disease control and quality of life after multiple prior lines.